Drug Type Small molecule drug |
Synonyms N-methyl-[6-(2-furyl)pyrid-3-yl]methylamine |
Target |
Action inhibitors |
Mechanism CNDP1 inhibitors(carnosine dipeptidase 1 inhibitors), CNDP2 inhibitors(carnosine dipeptidase 2 inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Molecular FormulaC11H12N2O |
InChIKeyUDZJNNURWGNFCN-UHFFFAOYSA-N |
CAS Registry886851-44-1 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Metabolic Diseases | Preclinical | United Kingdom | 01 Mar 2025 | |
Obesity | Preclinical | United Kingdom | 01 Mar 2025 |